ArticleMicroorganisms2026
Technological Innovation and Consumer Trust: Understanding Safety Perceptions in Next Generation Probiotic Development.
Article in Microorganisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper examines how technological innovation in next-generation probiotics shapes consumer trust through the lens of perceived safety. Rapid advances-spanning conventional cultures (Tier 1), postbiotics (Tier 2), and engineered microbial strains (Tier 3)-are transforming functional food architectures, yet consumer trust remains a critical determinant of their successful development, application, and adoption. Drawing on interdisciplinary evidence from food microbiology, consumer perception research, and regulatory analysis, this study examines and evaluates how these distinct technological innovation tiers alter public risk dynamics. Findings indicate that processing methodologies, media framing, and the spread of misinformation significantly influence public perceptions of microbial legitimacy, while the "Animation Gap" and "Contamination Anxiety" introduce qualitatively new cognitive friction points. Furthermore, regulatory inconsistencies across jurisdictions and variability in health claim substantiation further complicate market uptake. Streamlined case-based evidence highlights physical stability, sensory performance, and explicit value metrics that determine whether technological innovations are trusted or rejected by consumers. The paper argues that bridging the gap between scientific innovation and public acceptance requires proactive communication strategies, ethical marketing practices, and participatory engagement strategies grounded in empirical integrity. In addition, digital ecosystems, including social media and algorithm-driven content exposure, play an increasingly influential role in amplifying technology neophobia, underscoring the need for robust, targeted, evidence-based public communication in the evolving landscape of probiotic and functional food innovation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.